Given the fact that elderly GBM patients are more likely to be IDH1 wild-type and Mes subtype of GBM than younger patients [34], [35], [36], they may not draw survival benefit with BEV therapy as younger patients do (see P3, Figure 2, Figure 3 and Table 6). This evidence concerns the gene IDH1 and glioblastoma.